Tag Archives: The State of Patent Eligibility

CardioNet v. Infobionics: The Requirement for Improvements in Patent Eligibility

Posted on April 20, 2020 by Warren Woessner

This decision, Appeal No. 2019-1149 (Fed. Cir. April 17th 2020) should have required about 13 pages and could have ended after the first paragraph under Section A. Instead, a split panel required a 23 page majority decision and a 10 … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Solicitor General’s Briefs Encourage Supreme Court to Put s. 101 Back on Track

Posted on December 10, 2019 by Warren Woessner

Earlier this year, the Supreme Court issued orders to the Solicitor General to weigh in on whether or not the Court should grant cert. in two high profile Fed. Cir. decisions: Hikma Pharm. USA Inc, v. Vanda Pharm. Inc., No. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

October 2019 Update: Subject Matter Eligibility – A Closer Look

Posted on October 30, 2019 by Edward Sandor

Guest post from Edward Sandor. Warren Woessner also posted a blog about the Updated Guidance on October 21. On October 17, 2019, the USPTO published an October 2019 Patent Eligibility Guidance Update to the earlier 2019 Revised Patent Subject Matter … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Athena’s “Questionable” Petition for Cert.

Posted on October 8, 2019 by Warren Woessner

On October 1st, Athena filed a petition for a writ of certiorari to the Supreme Court following the Fed. Cir.’s fractured denial for its petition for rehearing en banc in Amgen v. Mayo. The original request for rehearing en banc … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment